Search Results - "Goyal, Jaya"
-
1
Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
Published in Multiple sclerosis (01-11-2020)“…Background: Neurofilament light chain (NfL) is a promising marker of disease activity/treatment response in multiple sclerosis (MS), although its predictive…”
Get full text
Journal Article -
2
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Published in Blood (16-01-2014)“…This phase 3 pivotal study evaluated the safety, efficacy, and pharmacokinetics of a recombinant FVIII Fc fusion protein (rFVIIIFc) for prophylaxis, treatment…”
Get full text
Journal Article -
3
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Published in The New England journal of medicine (12-12-2013)“…A fusion protein comprising factor IX and the dimeric Fc domain of IgG1 has a half-life that is five times as long as that of native factor IX, allowing…”
Get full text
Journal Article -
4
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring
Published in Multiple sclerosis (01-09-2021)“…Objective: To understand how longitudinal serum neurofilament light chain (sNfL) patterns can inform its use as a prognostic biomarker in multiple sclerosis…”
Get full text
Journal Article -
5
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Published in Blood (29-03-2012)“…Current factor VIII (FVIII) products display a half-life (t1/2) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of…”
Get full text
Journal Article -
6
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
Published in Blood (19-01-2012)“…Current factor IX (FIX) products display a half-life (t1/2) of ∼ 18 hours, requiring frequent intravenous infusions for prophylaxis and treatment in patients…”
Get full text
Journal Article -
7
Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis
Published in PloS one (18-11-2014)“…A subset of patients with autoimmune diseases including rheumatoid arthritis (RA) and lupus appear to be exposed continually to interferon (IFN) as evidenced…”
Get full text
Journal Article -
8
Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis
Published in PloS one (20-11-2013)“…Meningeal inflammation, including the presence of semi-organized tertiary lymphoid tissue, has been associated with cortical pathology at autopsy in secondary…”
Get full text
Journal Article -
9
Investigational Assay for Haplotype Phasing of the Huntingtin Gene
Published in Molecular therapy. Methods & clinical development (11-12-2020)“…Novel treatments for Huntington’s disease (HD), a progressive neurodegenerative disorder, include selective targeting of the mutant allele of the huntingtin…”
Get full text
Journal Article -
10
Analysis of Normal Epithelial Cell Specific-1 (NES1)/Kallikrein 10 mRNA Expression by in Situ Hybridization, a Novel Marker for Breast Cancer
Published in Clinical cancer research (01-11-2001)“…Purpose: Normal epithelial cell specific-1 ( NES1 )/ kallikrein 10 gene is expressed in normal mammary and prostate epithelial cells, but the expression of…”
Get full text
Journal Article -
11
Assay Formats: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team
Published in The AAPS journal (01-03-2014)“…As part of the GBC (Global Bioanalysis Consortium), the L3 assay format team has focused on reviewing common platforms used to support ligand binding assays in…”
Get full text
Journal Article -
12
Translational biomarkers: from discovery and development to clinical practice
Published in Drug discovery today. Technologies (01-09-2016)“…The refinement of disease taxonomy utilizing molecular phenotypes has led to significant improvements in the precision of disease diagnosis and customization…”
Get full text
Journal Article -
13
PGN-EDODM1: Preclinical Data Supporting the Development of an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Myotonic Dystrophy Type 1 (DM1) (S48.001)
Published in Neurology (25-04-2023)“…Abstract only…”
Get full text
Journal Article -
14
PGN-EDO51: Preclinical Data Supporting the Development of an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Duchenne Muscular Dystrophy (DMD) (P3-8.002)
Published in Neurology (25-04-2023)“…Abstract only…”
Get full text
Journal Article -
15
Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics
Published in Journal of immunological methods (01-06-2014)“…Many biotherapeutics currently in development have complex mechanisms of action and contain more than one domain, each with a specific role or function…”
Get full text
Journal Article -
16
PGN-EDO51, an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Duchenne Muscular Dystrophy (DMD): Results of a Phase 1 Study in Healthy Volunteers (P3-8.004)
Published in Neurology (25-04-2023)“…Abstract only…”
Get full text
Journal Article -
17
Centrally sponsored schemes in Andaman and Nicobar Islands: a governance paradox
Published in International journal of sociology and social policy (01-01-2014)“…Purpose – The purpose of this paper is to present the Andaman and Nicobar Islands (ANI) as a case to delineate contextual and often paradoxical challenges in…”
Get full text
Journal Article -
18
-
19
Accountability, Nutrition and Local Institutions in India
Published in Development (Society for International Development) (01-01-2015)“…In contemporary governance discourse, accountability is found linked to almost every conceivable aspect of ‘good governance’ – from developmental effectiveness…”
Get full text
Journal Article -
20
Pre-Existing Biotherapeutic-Reactive Antibodies: Survey Results Within the American Association of Pharmaceutical Scientists
Published in The AAPS journal (01-07-2013)“…The immunogenicity profile of a biotherapeutic is determined by a multitude of product and patient-related risk factors that can influence the observed…”
Get full text
Journal Article